Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 30:13:1077794.
doi: 10.3389/fonc.2023.1077794. eCollection 2023.

Impact of endobiliary radiofrequency ablation on survival of patients with unresectable cholangiocarcinoma: a narrative review

Elena Di Girolamo  1 , Andrea Belli  2 , Alessandro Ottaiano  3 , Vincenza Granata  4 , Valentina Borzillo  5 , Luca Tarotto  6 , Fabiana Tatangelo  7 , Raffaele Palaia  8 , Corrado Civiletti  1 , Mauro Piccirillo  2 , Valentina D'Angelo  1 , Francesco Fiore  6 , Pietro Marone  1 , Guglielmo Nasti  3 , Francesco Izzo  2 , Mario de Bellis  1
Affiliations
Review

Impact of endobiliary radiofrequency ablation on survival of patients with unresectable cholangiocarcinoma: a narrative review

Elena Di Girolamo et al. Front Oncol. .

Abstract

Cholangiocarcinoma (CCA) is a rare cancer originating from the biliary epithelium and accounts for about 3% of all gastrointestinal malignancies. Unfortunately, the majority of patients are not eligible for surgical resection at the time of diagnosis, because of the locally advanced stage or metastatic disease. The overall survival time of unresectable CCA is generally less than 1 year, despite current chemotherapy regimens. Biliary drainage is often required as a palliative treatment for patients with unresectable CCA. Recurrent jaundice and cholangitis tend to occur because of reobstruction of the biliary stents. This not only jeopardizes the efficacy of chemotherapy, but also causes significant morbidity and mortality. Effective control of tumor growth is crucial for prolonging stent patency and consequently patient survival. Recently, endobiliary radiofrequency ablation (ERFA) has been experimented as a treatment modality to reduce tumor mass, and delay tumor growth, extending stent patency. Ablation is accomplished by means of high-frequency alternating current which is released from the active electrode of an endobiliary probe placed in a biliary stricture. It has been shown that tumor necrosis releases intracellular particles which are highly immunogenic and activate antigen-presenting cells, enhancing local immunity directed against the tumor. This immunogenic response could potentially enhance tumor suppression and be responsible for improved survival of patients with unresectable CCA who undergo ERFA. Several studies have demonstrated that ERFA is associated with an increased median survival of approximately 6 months in patients with unresectable CCA. Furthermore, recent data support the hypothesis that ERFA could ameliorate the efficacy of chemotherapy administered to patients with unresectable CCA, without increasing the risk of complications. This narrative review discusses the results of the studies published in recent years and focuses on the impact that ERFA could have on overall survival of patients with unresectable cholangiocarcinoma.

Keywords: ERCP; PTC; biliary drainage; biliary stent patency; cholangiocarcinoma; endobiliary radiofrequency ablation; malignant biliary strictures; overall survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Pathophysiology of Endobiliary Radiofrequency Ablation (ERFA) (modified from 25).
Figure 2
Figure 2
Proposed algorithm for Endobiliary Radiofrequency Ablation (ERFA) in the management of jaundiced patients with locally advanced unresectable cholangiocarcinoma (NR-CCA), Bismuth type I-III (modified from 8 and 23).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Pantano F, Iuliani M, Simonetti S, Tonini G. Colecisti e vie biliari. In: Airtum, I numeri del cancro in italia (2021). AIOM (Intermedia Editore; (2021). p. 55–6. Available at: https://www.aiom.it/wpcontent/uploads/2021/10/2021_NumeriCancro_web.pdf.
    1. Dondossola D, Ghidini M, Grossi F, Rossi G, Foschi D. Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. World J Gastroenterol (2020) 26(25):3542–61. doi: 10.3748/wjg.v26.i25.3542 - DOI - PMC - PubMed
    1. Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Heinz-Josef Klümpen H-J, et al. . Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA registry. J Hepatol (2021) 1–13. doi: 10.1016/j.jhep.2021.12.010 - DOI - PubMed
    1. Banales JM, Marin JGJ, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. . Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol (2020) 17:557–88. doi: 10.1038/s41575-020-0310-z - DOI - PMC - PubMed
    1. O’Brien S, Bhutiani N, Egger ME, Brown AN, Weaver KH, Kline D, et al. . Comparing the efficacy of initial percutaneous transhepatic biliary drainage and endoscopic retrograde cholangiopancreatography with stenting for relief of biliary obstruction in unresectable cholangiocarcinoma. Surg Endosc (2020) 34(3):1186–90. doi: 10.1007/s00464-019-06871-2 - DOI - PubMed

LinkOut - more resources